Zhanjiang, China

Denghui Li

This inventor holds 1 USPTO granted patent and 5 published patent applications and 1 EPO patent. Top assignee: Guangdong Ocean University. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Denghui Li. Retrieved from https://idiyas.com/inventor/denghui-li

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Denghui Li

Introduction

Denghui Li is an inventor based in Shenzhen, China. He is known for his contributions to the field of biotechnology, particularly in the development of helicase BCH1X. Although he currently holds no granted patents, his work in patent applications showcases his innovative spirit and dedication to advancing scientific knowledge.

Latest Patent Applications

Denghui Li's notable patent application is for the helicase BCH1X and its use. This application provides a detailed description of helicase BCH1X, which comprises an amino acid sequence represented by SEQ ID NO: 1 or 2. Additionally, it includes a complex structure comprising helicase BCH1X and a binding moiety used for binding to a polynucleotide. The application outlines the use of this helicase in the control and characterization of a polynucleotide and in single molecule nanopore sequencing.

Conclusion

Denghui Li's innovative work in biotechnology, particularly with helicase BCH1X, highlights his potential as an inventor in the field. His ongoing efforts in patent applications reflect his commitment to scientific advancement and innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…